rituximab + chemotherapy (Roche)

rituximab + chemotherapy refers to the combination of the anti-CD20 monoclonal antibody rituximab with cytotoxic chemotherapy agents for the treatment of B-cell chronic lymphocytic leukemia (CLL). Rituximab, developed by Hoffmann-La Roche and Biogen, targets the CD20 protein on the surface of B-cells, leading to cell depletion via antibody-dependent cellular cytotoxicity (ADCC) and complement-dependent cytotoxicity (CDC). The chemotherapy component typically includes agents such as fludarabine and cyclophosphamide (FCR) or bendamustine (BR), which act by damaging DNA and inhibiting cell division. This chemoimmunotherapy approach was the standard of care for CLL for many years, significantly improving outcomes compared to chemotherapy alone. The specific context provided relates to Roche's observational studies monitoring the safety and efficacy of this combination in real-world clinical settings.

Brand names

MabTheraRituxan

Other names

R-chemoRituximab-chemotherapy